GSK's Specialty Medicines Drive Solid Results

Core Insights - The pharma company achieved double-digit percentage growth in its immunology and inflammation, oncology, and HIV portfolios for 2025, with total sales reaching £32.67 billion [1] Group 1 - The company reported significant growth in its immunology and inflammation portfolio [1] - The oncology portfolio also experienced double-digit percentage growth [1] - The HIV portfolio contributed to the overall sales increase, reflecting strong performance [1]